CA2531810A1 - Compositions et procede pour traiter la maladie de parkinson et la diskynesie tardive - Google Patents

Compositions et procede pour traiter la maladie de parkinson et la diskynesie tardive Download PDF

Info

Publication number
CA2531810A1
CA2531810A1 CA002531810A CA2531810A CA2531810A1 CA 2531810 A1 CA2531810 A1 CA 2531810A1 CA 002531810 A CA002531810 A CA 002531810A CA 2531810 A CA2531810 A CA 2531810A CA 2531810 A1 CA2531810 A1 CA 2531810A1
Authority
CA
Canada
Prior art keywords
quinoline
composition
amino
diethylamino
methylbutylamino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002531810A
Other languages
English (en)
Inventor
Jodi Nelson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alpha Research Group LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/192,414 external-priority patent/US20020198231A1/en
Application filed by Individual filed Critical Individual
Publication of CA2531810A1 publication Critical patent/CA2531810A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne des compositions et des procédés pour améliorer la respiration cellulaire des neurones produisant de la catécholamine mélanisée, et des procédés pour trouver les symptômes ou stopper l'apparence et/ou la progression des symptômes de la maladie de Parkinson et des états pathologiques associés. L'invention est caractérisée par la dégénérescence nigro-striée, ainsi que la dyskinésie induite par les médicaments, une diskynésie tardive, un syndrome malin neuroleptique, et des symptômes négatifs de la schizophrénie. Une quantité efficace d'une composition de liaison de la neuromélanine présentant un noyau de quinoline dans une porteuse pharmaceutiquement acceptable est administrée à un patient qui a besoin d'un tel traitement. De préférence, la composition comprend (-)-chloroquine diphosphate. L'invention concerne également des additifs sélectionnés en tant que partie des compositions de l'invention.
CA002531810A 2002-07-09 2003-07-09 Compositions et procede pour traiter la maladie de parkinson et la diskynesie tardive Abandoned CA2531810A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US10/192,414 2002-07-09
US10/192,414 US20020198231A1 (en) 1999-07-13 2002-07-09 Compositions and methods for the treatment of Parkinson's disease
US47974803P 2003-06-19 2003-06-19
US60/479,748 2003-06-19
PCT/US2003/021463 WO2004004660A2 (fr) 2002-07-09 2003-07-09 Compositions et procede pour traiter la maladie de parkinson et la diskynesie tardive

Publications (1)

Publication Number Publication Date
CA2531810A1 true CA2531810A1 (fr) 2004-01-15

Family

ID=30117814

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002531810A Abandoned CA2531810A1 (fr) 2002-07-09 2003-07-09 Compositions et procede pour traiter la maladie de parkinson et la diskynesie tardive

Country Status (5)

Country Link
EP (1) EP1581167A4 (fr)
JP (1) JP2006514917A (fr)
AU (1) AU2003248893A1 (fr)
CA (1) CA2531810A1 (fr)
WO (1) WO2004004660A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007067714A2 (fr) 2005-12-08 2007-06-14 The Mclean Hospital Corporation Traitement de séquelles de troubles psychiatriques
CN101466380A (zh) * 2006-02-16 2009-06-24 麦克莱恩医院 治疗帕金森病的方法和组合物
CA2760825C (fr) * 2009-06-03 2017-07-11 Marquette University Modulation de l'activite du canal de potassium de kcnq dans le traitement de troubles psychiatriques et de symptomes afferents
US8901129B2 (en) 2009-12-11 2014-12-02 Genecode As Methods of facilitating neural cell survival using GDNF family ligand (GFL) mimetics or RET signaling pathway activators
CN113354581B (zh) * 2020-03-06 2023-06-20 华南理工大学 手性氯喹及其磷酸盐的制备方法及其应用
CN113527201A (zh) * 2020-04-14 2021-10-22 瀚海新拓(杭州)生物医药有限公司 光学活性氯喹和羟氯喹及其类似物、其制备方法、组合物和用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5430039A (en) * 1990-09-28 1995-07-04 Cephalon, Inc. Treatment of neurological disorders
US5496836A (en) * 1994-05-05 1996-03-05 Mount Sinai School Of Medicine Of The City University Of New York Use of famotidine and related compounds in the treatment of movement disorders
DE4428199A1 (de) * 1994-08-09 1996-02-15 Univ Ludwigs Albert Verwendung von Flunitrazepam und/oder Chloroquin zur Behandlung von Spätdyskinesien
CA2416233A1 (fr) * 1999-07-13 2001-01-18 Alpha Research Group, Llc Traitement de la maladie de parkinson et compositions a cet effet

Also Published As

Publication number Publication date
EP1581167A4 (fr) 2008-10-29
EP1581167A2 (fr) 2005-10-05
AU2003248893A1 (en) 2004-01-23
WO2004004660A2 (fr) 2004-01-15
JP2006514917A (ja) 2006-05-18
AU2003248893A8 (en) 2004-01-23
WO2004004660A3 (fr) 2005-11-03

Similar Documents

Publication Publication Date Title
US20040229908A1 (en) Compositions and methods for the treatment of Parkinson's disease and tardive dyskinesias
US6417177B1 (en) Chloroquine derivatives for the treatment of Parkinson's disease
US6232326B1 (en) Treatment for schizophrenia and other dopamine system dysfunctions
JP4767982B2 (ja) 末梢または中枢神経障害およびサイトカイン過剰産生の治療のためのｋ−２５２ａ誘導体の使用
JP4755599B2 (ja) 緑内障性網膜症および視神経障害の処置のための薬剤
US20120034193A1 (en) Treatment of neurotrophic factor mediated disorders
TW201436791A (zh) 大麻素與抗精神病藥物組合使用之技術
EP2310003B1 (fr) Inhibiteurs de la carnitine palmitoyltransférase-1 pour le traitement et la prévention de troubles provoqués par une délipidation du tissu nerveux
EA010430B1 (ru) Сочетание антагониста nmda-рецептора и селективного ингибитора обратного захвата серотонина для лечения депрессии и других психических расстройств
US20020198231A1 (en) Compositions and methods for the treatment of Parkinson's disease
CA2531810A1 (fr) Compositions et procede pour traiter la maladie de parkinson et la diskynesie tardive
Baba et al. Anti-cholinergics for axial symptoms in Parkinson's disease after subthalamic stimulation
NZ236055A (en) Use of pyrimidine-substituted piperazine derivative in the treatment of depression
PL208258B1 (pl) Nowe zastosowanie 2-[5-(4-fluorofenylo) -3- pirydylometyloaminometylo] -chromanu oraz jego fizjologicznie tolerowanych soli
WO2009140859A1 (fr) Utilisation de dérivés de la l-stépholidine (l-spd)
JP2005306882A (ja) 感情的不安定の治療のための医薬の製造に有用な組成物
WO2012154710A1 (fr) Traitement de troubles cognitifs par certains agonistes du récepteur nicotinique alpha-7 en combinaison avec la nicotine
WO2020110128A1 (fr) Combinaison de pridopidine et d'un agent thérapeutique additionnel pour le traitement de la dyskinésie induite par un médicament
Küçükoğlu et al. Parkinson's Disease, Therapy with Drugs and Nanotechnology
EP3868373B1 (fr) Utilisation d'un composé cannabinoïde pour le traitement de la neurodermatite
US20240293435A1 (en) Methods and Compositions for Treating Human Disorders Using D-Cycloserine and a Psychedelic Agent
WO2023196668A2 (fr) Promédicaments pour le traitement du cancer
EP4175643A1 (fr) Compositions et procédés pour traiter des troubles psychiatriques ou des symptômes de ceux-ci
JP4372723B2 (ja) 慢性疼痛の治療のための医薬の製造に有用な組成物
Tomar et al. Exploring Cannabidiol [CBD] as a Therapeutic Agent in Neurodegenerative Disorders

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead